Abe Durrant
YOU?
Author Swipe
View article: Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer’s Disease: Synthesis of Evidence from Observational and Interventional Trials
Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer’s Disease: Synthesis of Evidence from Observational and Interventional Trials Open
Amyloid-plaque reduction is currently the only recognized surrogate outcome for Alzheimer's disease (AD) trials, allowing accelerated approval of plaque-clearing amyloid antibodies. However, plaque reduction does not facilitate the develop…
View article: Cerebral oxygenation when ventilated or spontaneously breathing: a randomised control trial
Cerebral oxygenation when ventilated or spontaneously breathing: a randomised control trial Open
This trial was retrospectively registered on 10/2/2023 with the ANZCTR. TRN ACTRN12623000143628.
View article: Efficacy Assessment in Trials of Complex and Rare Diseases: A Comparison Between the Meta-Analytic Global Statistical Test and Co-Primary Analysis
Efficacy Assessment in Trials of Complex and Rare Diseases: A Comparison Between the Meta-Analytic Global Statistical Test and Co-Primary Analysis Open
Background: Complex and rare diseases often have heterogeneous symptoms, which complicates the selection of an appropriate primary outcome because outcome assessments rarely capture all aspects of disease. Disease-modifying treatments (DMT…
View article: Leukocyte Surface Biomarkers for Clinical Diagnosis of Sporadic Alzheimer’s Disease
Leukocyte Surface Biomarkers for Clinical Diagnosis of Sporadic Alzheimer’s Disease Open
Background Mounting evidence indicates that the accumulation of amyloid in AD starts 20 to 30 years before clinically detectable cognitive impairment is observed, suggesting the presence of a long period of asymptomatic AD. Although the sp…
View article: Clinical Utility of U‐p53AZ as a prognostic biomarker for the prediction of progression rate, in individuals with early stages of Alzheimer’s Disease
Clinical Utility of U‐p53AZ as a prognostic biomarker for the prediction of progression rate, in individuals with early stages of Alzheimer’s Disease Open
Background Despite recent success in AD clinical trials, many obstacles still prevent effectively halting disease progression. Many suspect that treating subjects earlier in the disease process will be key to providing more effective treat…
View article: Results of the ACTION‐Galactosemia Kids Study to Evaluate the Effects of Govorestat in Pediatric Patients with Classic Galactosemia
Results of the ACTION‐Galactosemia Kids Study to Evaluate the Effects of Govorestat in Pediatric Patients with Classic Galactosemia Open
To evaluate the pharmacodynamic effects and clinical outcomes of orally administered once‐daily govorestat (AT‐007), a central nervous system penetrant aldose reductase inhibitor, the double‐blind placebo‐controlled ACTION‐Galactosemia Kid…